OTUD6B‑Related Neurodevelopmental Disorder (IDDFSDA) — Comprehensive Research Report

Prepared: 2026‑08‑01 · Target entity: OTUD6B‑Related Neurodevelopmental Disorder · MONDO:0044319

⚠️ Curation Preflight Notes (read before using this report)

Three disambiguation hazards apply to this entity and should be treated as Named Entity Confusion (NEC) risk per the dismech DR SOP:

1. OTUD6B-AS1 is a different molecular entity. Of ~76 PubMed records for "OTUD6B," the large majority (≈40) concern OTUD6B‑AS1, a long non‑coding antisense RNA transcribed at the same 8q21.3 locus, studied almost exclusively as a cancer biomarker (breast, colorectal, cervical, thyroid, bladder). None of these bear on the neurodevelopmental disorder. Do not cite OTUD6B‑AS1 papers as OTUD6B evidence.
2. OTUD7A is a different DUB / different NDD gene. OTUD7A (15q13.3 microdeletion driver, MIM 612024) also causes a DUB‑related NDD with epilepsy and ID (PMID:36604605). It is a sister-gene confusion, not the same disease.
3. OTUD6A is a paralog at Xq26.1, not currently a Mendelian disease gene.

MONDO identity anchors verified: MONDO:0044319 carries xrefs OMIM:617452, Orphanet:505237, GARD:0017942, MEDGEN:1375601, UMLS:C4479520, and sits under MONDO:0000508 (syndromic intellectual disability) — matching the ClinGen gene‑disease validity assertion (below). Causal gene = OTUD6B. Preflight passes.

Protein numbering discrepancy to resolve before curating catalytic residues: UniProt canonical Q8N6M0 is a 293‑aa protein with the OTU domain at residues 147–284 and catalytic residues Cys158 (nucleophile) / His277. The original AJHG paper's full text (per PMC5384096) describes a 323‑aa protein with a predicted active site of "Asp185, Cys188, and His307" — an offset consistent with a longer alternative isoform's numbering. All clinically reported variants use NM_016023.5 / 293‑aa numbering (e.g., p.Lys291AsnfsTer3 is near the C‑terminus of a 293‑aa protein). Anchor on the 293‑aa numbering; flag the 323‑aa figures as isoform‑dependent.

Verbatim status of quotations below: Abstract text marked with > block quotes was retrieved verbatim from PubMed record pages and is suitable for evidence snippet: use after just fetch-reference + just validate-references. Figures attributed to PMC5384096 full text were extracted by an automated reader and are paraphrase-risk — verify against the article before using as snippets.

1. Disease Information

1.1 Overview

OTUD6B‑related neurodevelopmental disorder is a rare autosomal recessive multisystem developmental disorder caused by biallelic loss‑of‑function variants in OTUD6B, which encodes an ovarian‑tumour (OTU)‑domain deubiquitinating enzyme. The core phenotype is global developmental delay and intellectual disability with early‑onset seizures, a recognizable dysmorphic facial gestalt, and distal limb anomalies (notably broad distal phalanges/thumbs with persistent fetal fingertip pads). Prenatal‑onset growth restriction, microcephaly, hypotonia, feeding difficulty, structural brain anomalies, and congenital heart disease are frequent. Severity is strikingly bimodal: predicted‑null biallelic genotypes produce a severe, often non‑ambulatory, non‑verbal, gastrostomy‑dependent phenotype, whereas hypomorphic missense/leaky‑splice genotypes may produce only mild‑to‑moderate ID with preserved speech and ambulation.

The disorder was defined in 2017 by Santiago‑Sim et al. in the American Journal of Human Genetics (PMID:28343629), with 12 individuals from 6 families:

Ubiquitination is a posttranslational modification that regulates many cellular processes including protein degradation, intracellular trafficking, cell signaling, and protein-protein interactions. Deubiquitinating enzymes (DUBs), which reverse the process of ubiquitination, are important regulators of the ubiquitin system. OTUD6B encodes a member of the ovarian tumor domain (OTU)-containing subfamily of deubiquitinating enzymes. Herein, we report biallelic pathogenic variants in OTUD6B in 12 individuals from 6 independent families with an intellectual disability syndrome associated with seizures and dysmorphic features. In subjects with predicted loss-of-function alleles, additional features include global developmental delay, microcephaly, absent speech, hypotonia, growth retardation with prenatal onset, feeding difficulties, structural brain abnormalities, congenital malformations including congenital heart disease, and musculoskeletal features. Homozygous Otud6b knockout mice were subviable, smaller in size, and had congenital heart defects, consistent with the severity of loss-of-function variants in humans. Analysis of peripheral blood mononuclear cells from an affected subject showed reduced incorporation of 19S subunits into 26S proteasomes, decreased chymotrypsin-like activity, and accumulation of ubiquitin-protein conjugates. Our findings suggest a role for OTUD6B in proteasome function, establish that defective OTUD6B function underlies a multisystemic human disorder, and provide additional evidence for the emerging relationship between the ubiquitin system and human disease. — Santiago‑Sim T et al., Am J Hum Genet 2017;100(4):676‑688. doi:10.1016/j.ajhg.2017.03.001 (PMID:28343629)

1.2 Key identifiers

1.3 Synonyms and alternative names

• IDDFSDA (OMIM acronym)
• OTUD6B‑related syndrome / OTUD6B‑related disorder / OTUD6B‑associated intellectual disability
• Intellectual disability syndrome with seizures and dysmorphic features
• Early‑onset seizures–distal limb anomalies–facial dysmorphism–global developmental delay syndrome (Orphanet preferred term)

Gene aliases: CGI-77, DUBA5; previous HGNC symbol "OTU domain containing 6B".

1.4 Information provenance

This is an aggregated disease‑level entity, not an EHR‑derived one. The knowledge base is built entirely from published case reports and small family series (n ≈ 28–30 individuals worldwide as of 2025), plus curated aggregators (OMIM, Orphanet, ClinGen, HPO, ClinVar). There is no registry, no natural‑history cohort, and no EHR phenotype algorithm for this disorder. The 2025 BMC Pediatrics report states verbatim:

There have been < 30 reported cases globally without fundus and retinal lesions. — Novel variant causing OTUD6B-related syndrome with ocular dysplasia and hypothyroidism: the first Chinese case. BMC Pediatr. 2025 Nov 4;25(1):905 (PMID:41188742, PMC12584513)

2. Etiology

2.1 Disease causal factors

Single, monogenic cause: biallelic (homozygous or compound heterozygous) pathogenic variants in OTUD6B. No environmental, infectious, or multifactorial etiology has been described or is biologically plausible for this entity. The etiologic mechanism is loss of function of the OTUD6B deubiquitinase, with resulting perturbation of ubiquitin‑dependent proteostasis — specifically 26S proteasome assembly/activity — during embryonic and postnatal development.

2.2 Risk factors

Genetic (causal): - Two pathogenic OTUD6B alleles. Reported allele classes: nonsense, frameshift, canonical splice‑site (with demonstrated aberrant splicing), and rare missense variants localized to the OTU catalytic domain. - Consanguinity is the dominant risk amplifier. Reported families are overwhelmingly consanguineous — Turkish, Egyptian (two unrelated families, PMID:34354232), Saudi/Gulf, Mexican, Spanish, Italian, Chinese. Founder/recurrent alleles: c.433C>T (p.Arg145*) was homozygous in three of the six original families and independently in the Mexican proband, consistent with either a recurrent CpG transition or a shared haplotype. - Second‑locus / blended phenotypes — an under‑appreciated etiologic modifier in this disorder. Three published probands carry a second pathogenic locus that contributes phenotype: a homozygous RP1L1 nonsense variant causing retinal degeneration in Egyptian Family I (PMID:34354232); a heterozygous PKD1 variant contributing renal cystic disease alongside Tetralogy of Fallot (PMID:35707595); and a ZMIZ1 splice variant co‑occurring with an OTUD6B point mutation + 8q21.3 microdeletion (PMID:34680978).

Environmental risk factors: none identified. No toxin, exposure, maternal factor, parity, or ascertainment‑independent sex effect has been reported.

Age/sex: onset is congenital‑to‑infantile in all reported cases. No sex bias is expected (autosomal recessive); reported cohorts include both sexes with no reported skew, though n is far too small to test.

2.3 Protective factors

• Genetic: the only demonstrated modifier of severity is residual OTUD6B activity. Hypomorphic missense alleles and leaky splice alleles are associated with markedly milder disease. Two structural‑modelling studies make this explicit — PMID:35430327 concluded that p.Tyr216Cys (milder phenotype) causes "localized destabilization" whereas p.Ile274Arg (severe phenotype) causes "significant distortion in the overall fold of OTUD6B." Similarly, PMID:30364145's Italian proband with two splice variants retained "less than 1% of wild-type transcripts" yet had only mild ID — indicating that the genotype–severity map is not fully resolved and that trace residual protein may be disproportionately protective (or that other modifiers exist).
• Environmental protective factors: none identified. Standard heterozygote carriers are unaffected (pLI 0; see §4.2).

2.4 Gene–environment interactions

None established. One clinically relevant gene–physiology interaction is worth flagging for the pathograph: the Chinese proband's seizures were febrile ("two episodes of febrile seizure" at 13 and 17 months, PMID:41188742) — raising a hypothesis, currently unsupported by cohort data, that intercurrent illness/pyrexia lowers seizure threshold in this proteostasis disorder. This should be curated at most as a KNOWLEDGE_GAP discussion, not as an asserted mechanism.

3. Phenotypes

3.1 Authoritative HPO annotation set (OMIM:617452)

Retrieved from https://ontology.jax.org/api/network/annotation/OMIM:617452. Frequencies are the HPOA n/m counts, derived from the 12‑individual founding cohort (PMID:28343629) except cardiac terms, which are n/6.

Annotated without frequency: HP:0002119 Ventriculomegaly · HP:0002540 Inability to walk · HP:0001508 Failure to thrive · HP:0001371 Flexion contracture · HP:0000028 Cryptorchidism · HP:0000369 Low‑set ears · HP:0000411 Protruding ear · HP:0000377 Abnormal pinna morphology · HP:0000365 Hearing impairment · HP:0001276 Hypertonia · HP:0000527 Long eyelashes · HP:0000218 High palate · HP:0000276 Long face · HP:0000494 Downslanted palpebral fissures · HP:0005469 Flat occiput · HP:0000431 Wide nasal bridge · HP:0001762 Talipes equinovarus · HP:0001182 Tapered finger.

3.2 Post‑2017 phenotypic expansions (each from a specific report)

3.3 Phenotype characteristics

Age of onset. Congenital‑to‑infantile. Prenatal onset is documented in a substantial minority: IUGR is annotated with HPO onset term HP:0030674 (Antenatal onset) at 7/12, and one family had a pregnancy medically terminated for antenatally diagnosed Tetralogy of Fallot (PMID:35707595). Microcephaly and motor delay carry HPO onset HP:0003593 (Infantile onset). Orphanet records age of onset as infancy. GARD summarizes symptom emergence at 1–23 months.

Severity — a genuinely bimodal distribution. This is the single most curation‑relevant characteristic of the disorder and should be modelled as has_subtypes or at minimum as an explicit severity axis: - Severe (predicted‑null biallelic genotypes): microcephaly, absent speech, inability to walk, feeding‑tube dependence, spastic quadriplegia. MedGen summarizes: "The most severely affected patients have a neurodevelopmental disorder with microcephaly, absent speech, and inability to walk, and they require feeding tubes." - Mild (hypomorphic missense / leaky splice): "less severely affected individuals have mild to moderate intellectual disability with normal speech and motor development." The Italian proband (PMID:30364145) is the archetype — "mild intellectual disability, speech and motor delay, and recurrent seizures."

PMID:35430327 makes the genotype→severity link explicit and computational: "our findings support that the clinical severity could be related with the predicted functional severity of the variations in OTUD6B."

Critically, intra‑familial variability also exists — PMID:34354232: "our patients showed inter- and intrafamilial differences with regard to the clinical and brain imaging findings." This argues against a purely genotype‑determined severity model and supports curating an unresolved modifier gap.

Progression. No natural‑history study exists. The disorder is best characterized as a static (non‑degenerative) encephalopathy with a congenital structural/developmental basis — brain MRI shows malformation (corpus callosum hypoplasia, ventriculomegaly) rather than progressive atrophy in most reports, though cortical atrophy is listed by Orphanet. Seizures are recurrent/episodic on a chronic lifelong background. Scoliosis and contractures are expected to be progressive secondary orthopedic complications of hypotonia/spasticity. This progression characterization is an inference from the reported feature set, not a cited finding — flag as a knowledge gap.

Frequency evidence discipline. Per docs/frequency-evidence-guidelines.md, the HPOA n/12 counts are derived counts from the founding cohort and are acceptable justification for FrequencyEnum bands. However, they reflect a single ascertainment‑biased cohort of predominantly severe cases; frequencies for the mild end of the spectrum are almost certainly overstated (e.g., "Severe intellectual disability 12/12" is contradicted by later mild cases). Recommend curating the HPOA frequencies with an explicit note, or omitting frequency: for terms where the 2018–2025 literature conflicts with the 2017 cohort.

Quality of life. No EQ‑5D, PROMIS, SF‑36, or disease‑specific QoL instrument has been applied. The only QoL statement in the literature is a clinical aspiration, from PMID:32924626: "The current challenge with this patient is to ensure medical management of his seizures and provide him with a better quality of life." Expected QoL burden is dominated by (a) refractory seizures, (b) non‑verbal status and total care dependence in the severe group, (c) feeding‑tube dependence, and (d) caregiver burden. Mark as a knowledge gap.

4. Genetic / Molecular Information

4.1 Causal gene

OTUD6B (hgnc:24281; OMIM *612021; Entrez 51633; Ensembl ENSG00000155100; UniProt Q8N6M0), 8q21.3, reference transcript NM_016023.5. Encodes a 293‑aa cysteine‑protease deubiquitinase of the OTU family.

UniProt Q8N6M0 FUNCTION comment (verbatim):

[Isoform 1]: Deubiquitinating enzyme that may play a role in the ubiquitin-dependent regulation of protein synthesis, downstream of mTORC1. May associate with the protein synthesis initiation complex and modify its ubiquitination to repress translation. May also repress DNA synthesis and modify different cellular targets thereby regulating cell growth and proliferation. May also play a role in proteasome assembly and function. [Isoform 2]: Stimulates protein synthesis. Influences the expression of CCND1/cyclin D1 by promoting its translation and regulates MYC/c-Myc protein stability.

Domain architecture: N‑terminal coiled‑coil region + OTU catalytic domain, residues 147–284. Catalytic triad residues: Cys155/Cys158 (Cys158 is the nucleophile), His277. Cys→Ser mutation of the nucleophile abolishes DUB activity (functionally demonstrated in PMID:21267069: "Mutation of the conserved Cys residue abolished its deubiquitinating activity in vitro.").

Two functionally opposed splice isoforms. Isoform 2 (OTUD6B‑2) differs by replacement of residues 1–105 with "MISK." This is not a curatorial footnote — the isoforms have antagonistic effects on translation (PMID:27864334, §6.2), which is relevant to interpreting variant consequence: a variant in exon 1–3 may affect only OTUD6B‑1.

4.2 Gene constraint (gnomAD v4.0, via ClinGen)

These metrics are exactly what is expected for a recessive disease gene and should not be read as evidence against pathogenicity. Heterozygous carriers (including all obligate parents in the reported families) are unaffected. This is an important curation point: an automated pipeline keying on pLI would incorrectly deprioritize OTUD6B.

4.3 ClinGen gene–disease validity

Classification: DEFINITIVE. ClinGen (search.clinicalgenome.org/kb/genes/HGNC:24281) records one gene‑disease validity assertion:

• Gene: OTUD6B (HGNC:24281)
• Disease: syndromic intellectual disability (MONDO:0000508)
• Mode of inheritance: Autosomal recessive
• Classification: Definitive
• Expert panel: Intellectual Disability and Autism Gene Curation Expert Panel
• Date: 2024‑08‑22

No ClinGen dosage‑sensitivity, actionability, or variant‑pathogenicity curations exist for this gene. No CPIC/PharmGKB records. → A CGGV: structured‑source citation should be retrievable for this assertion via just clingen-refresh / just clingen-list.

4.4 Reported pathogenic variants (literature)

All in NM_016023.5 numbering. Zygosity as reported.

ClinVar (NM_016023.5) additional P/LP small variants not tied to a specific publication above, confirmed by esummary: - c.287del (p.Pro96fs) — Pathogenic — IDDFSDA - c.776C>G (p.Ser259Ter) — Pathogenic - c.381_388del (p.Leu127fs) — Pathogenic — IDDFSDA - c.401A>G (p.Glu134Gly) — Likely pathogenic — IDDFSDA - c.83-1del — Pathogenic — IDDFSDA (matches PMID:41188742)

ClinVar counts (2026‑08‑01, via E‑utilities): 151 total records for OTUD6B; 54 records classified P/LP. Important caveat: the majority of the 54 are large chromosome‑8 copy‑number gains/losses that merely span the locus, not gene‑level small variants. The number of distinct P/LP small OTUD6B variants is on the order of 10–15. Do not cite "54 pathogenic OTUD6B variants" without this qualification.

Variant spectrum summary: - Class distribution: nonsense ≈ 4; frameshift ≈ 4; canonical splice ≈ 4; missense ≈ 5 (all within or adjacent to the OTU domain: Tyr160, Tyr216, Gly256, Ile272/274 — plus Glu134 just N‑terminal); one whole‑gene microdeletion in trans with a point mutation. - Missense clustering in the OTU domain (147–284) is a notable pattern supporting a domain‑restricted missense hotspot and useful for PM1‑type ACMG evidence. - Somatic vs germline: all disease variants are germline. Somatic OTUD6B alteration is not a described mechanism in this disorder; OTUD6B's cancer roles (§6.2) are expression‑level, not mutational. - Allele frequency: all reported disease alleles are absent or ultra‑rare in gnomAD. PMID:30364145 states verbatim: "Both variants are reported in the GnomAD database with a frequency lower than the 10‑5 and affect the donor splicing site, of exons 2 and 3, respectively." - Functional consequence: loss of function throughout. Nonsense/frameshift alleles are predicted to trigger NMD (explicitly modelled in PMID:35430327: "The truncating frameshift variant in one allele was predicted to undergo degradation via nonsense-mediated decay of the mRNA molecule."); splice alleles cause exon skipping with near‑total loss of wild‑type transcript; missense alleles cause fold destabilization of varying severity. No gain‑of‑function or dominant‑negative mechanism has been proposed.

4.5 Functional validation of splice variants

PMID:30364145 provides the strongest direct RNA evidence in the disorder:

RT-PCR experiments demonstrated that both variants affect OTUD6B splicing and lead to the production of aberrant transcripts, the major ones being, in both cases, the skipping of the upstream exon. Quantitative analysis performed by competitive-fluorescent RT-PCR on the patient RNA showed that the proband presents less than 1% of wild-type transcripts, further strengthening the causative role of these variants.

4.6 Modifier genes, epigenetics, chromosomal abnormalities

• Modifier genes: none identified. The three "blended phenotype" second loci (RP1L1, PKD1, ZMIZ1) are independent co‑occurring conditions, not modifiers of the OTUD6B phenotype — PMID:34354232 is explicit that "Retinal degeneration, albeit present in both patients from Family I, was shown to be unrelated to OTUD6B." This is a valuable curation exemplar of DR‑style over‑attribution risk.
• Epigenetics: No episignature has been published for OTUD6B‑related disorder. (Given the Kabuki‑syndrome mimicry documented in PMID:38389298 and PMID:30364145, this is a concrete, high‑value research gap — DNA‑methylation episignature classifiers already discriminate Kabuki syndrome, so an OTUD6B episignature would be a plausible diagnostic advance.) No data available.
• Chromosomal abnormalities: one reported case with a 0.118 Mb paternally inherited deletion of 8q21.3 (chr8:92,084,087–92,202,189) encompassing OTUD6B, in trans with a maternal point mutation (PMID:34680978). This establishes that CMA can contribute the second hit and must be part of the diagnostic strategy (§10.2). Verbatim: "The CMA showed a paternally inherited 0.118 Mb deletion of 8q21.3, chr8:92084087-92202189, with OTUD6B involved."

5. Environmental Information

Not applicable. OTUD6B‑related neurodevelopmental disorder is a fully penetrant monogenic recessive condition. There are no reported environmental factors, lifestyle factors, toxicant exposures, or infectious agents that cause, trigger, or modify this disorder. No CTD/TOXNET association exists.

Two peripheral points worth recording as non‑etiologic: - The febrile trigger for the two seizures in the 2025 Chinese case (PMID:41188742) is a symptom‑precipitant observation, not an environmental etiology. - OTUD6B has documented antiviral innate‑immunity roles (§6.6). Whether patients with biallelic LoF have altered antiviral responses has not been tested in humans and must not be asserted. The reported hypogammaglobulinemia in three patients (PMID:32924626) is the only human immune signal.

6. Mechanism / Pathophysiology

6.1 The primary disease mechanism: impaired 26S proteasome assembly

This is the only mechanism established in patient material and should be the backbone of the pathograph.

Causal chain (patient‑derived, PMID:28343629):

Biallelic LoF OTUD6B variant  [MOLECULAR]
  → Loss of OTUD6B deubiquitinase activity  [MOLECULAR]
    → Reduced incorporation of 19S regulatory-particle subunits into 26S proteasomes;
      accumulation of 19S precursor complexes  [MOLECULAR]
      → Decreased 26S chymotrypsin-like peptidase activity  [MOLECULAR]
→ Accumulation of ubiquitin-protein conjugates; cytoplasmic inclusions in lymphocytes  [CELLULAR]
  → Impaired proteostasis in developing neural, cardiac and skeletal tissue  [TISSUE]
    → Multisystem developmental disorder  [ORGANISM]

The abstract‑level evidence sentence (verbatim, PMID:28343629): "Analysis of peripheral blood mononuclear cells from an affected subject showed reduced incorporation of 19S subunits into 26S proteasomes, decreased chymotrypsin-like activity, and accumulation of ubiquitin-protein conjugates."

Quantitative detail from the full text (PMC5384096) — ⚠️ paraphrase‑risk, verify before citing as snippets: - Native PAGE: "substantially reduced incorporation of Rpn5 and Rpt6 subunits into 26S proteasomes," with Rpn5 reduced by ~65% (heterozygote) and ~90% (homozygote) vs. wild‑type. - 26S chymotrypsin‑like activity reduced ~20% in homozygote vs. heterozygote. - "19S precursor complexes accumulate in both heterozygous and homozygous subjects but not in wild-type controls." - Ubiquitin‑protein conjugates "accumulated much stronger in the homozygous sample than in the heterozygous one." - Proposed mechanism (authors' speculation, flagged as such in the paper): "any impaired de-ubiquitination of proteasome subunits (including Rpn10, Rpn13, or Rpt5) might impact proteasome assembly and/or function," as "formation of 26S complexes is a process regulated by ubiquitin modification."

Note the gene‑dosage gradient: heterozygous carriers show intermediate biochemical abnormality (19S precursor accumulation, 65% Rpn5 reduction) while remaining clinically unaffected. This is a clean example of a biochemical phenotype that is subclinical in carriers — useful for a biochemical marker node with a carrier‑vs‑affected interpretation band.

6.2 Translation regulation downstream of mTORC1 (isoform‑opposed)

PMID:27864334 (in vitro, NSCLC cells) established the second major cellular function, verbatim:

Here, evidence is presented that the deubiquitinase OTUD6B regulates protein synthesis in non-small cell lung cancer (NSCLC) cells, operating downstream from mTORC1. OTUD6B associates with the protein synthesis initiation complex and modifies components of the 48S preinitiation complex. The two main OTUD6B splicing isoforms seem to regulate protein synthesis in opposing fashions: the long OTUD6B-1 isoform is inhibitory, while the short OTUD6B-2 isoform stimulates protein synthesis. […] OTUD6B-2 influences the expression of cyclin D1 by promoting its translation while regulating (directly or indirectly) c-Myc protein stability.

Relevance to the NDD: mTORC1‑coupled translational control is a canonical neurodevelopmental/epilepsy axis (cf. tuberous sclerosis, PMSE, focal cortical dysplasia). This provides a mechanistically coherent — but not experimentally demonstrated in neurons — bridge from OTUD6B loss to cortical malformation and seizure. Curate as a mechanistic_hypotheses entry with status: EMERGING, and attach the causal edge to that hypothesis group. Do not assert it as established human disease mechanism.

6.3 Cell‑cycle control (G1/S)

Two independent lines: - PMID:21267069 (mouse Ba/F3 cells + primary B lymphocytes): "Enforced expression of OTUD-6B in Ba/F3 cells could block cell proliferation by arresting cells in G1 phase. In addition, cyclin D2 level was down-regulated when OTUD-6B WT was overexpressed." Also documents post‑transcriptional control — Otud-6b mRNA is destabilized by tristetraprolin (TTP) via AU‑rich elements. - PMID:36059274 (multiple myeloma, EMBO J 2022): "we screened for DUB vulnerabilities in multiple myeloma […] and identified OTUD6B as an oncogene that drives the G1/S-transition. LIN28B, a suppressor of microRNA biogenesis, is specified as a bona fide cell cycle-specific substrate of OTUD6B. Stabilization of LIN28B drives MYC expression at G1/S, which in turn allows for rapid S-phase entry."

Note the direction conflict: OTUD6B overexpression is anti‑proliferative in B lymphocytes (2011) but pro‑proliferative via LIN28B‑MYC in myeloma (2022) and isoform‑dependent in NSCLC (2017). OTUD6B's proliferative effect is therefore context‑ and isoform‑dependent, and it is not safe to infer a single direction of effect on neural progenitor proliferation. This is a legitimate KNOWLEDGE_GAP for the NDD pathograph: does OTUD6B loss reduce or expand the neural progenitor pool, and is microcephaly proliferative or apoptotic in origin?

6.4 Stress granule dynamics via VCP/p97 — the most neurologically suggestive recent mechanism

PMID:41651815 (Cell Death Dis 2026), verbatim:

By combining interactomic and proximity proteomic approaches, we reveal that the deubiquitinating enzyme OTUD6B is associated with SG-related functions. Immunofluorescence assays showed that OTUD6B localized to SGs, as well as regulated their early assembly and clearance, partially dependent on its enzymatic activity. Further proximity proteomics and interactomics results uncover the ATPase VCP/p97, a key SG disassembly factor, as an OTUD6B-associated protein. OTUD6B and VCP association is governed through their disordered regions normally participated in biomolecular condensation. VCP knockdown or pharmacological inhibition phenocopied OTUD6B silencing by leading to defects in SG dynamics. […] Therefore, our findings establish OTUD6B as a critical modulator of SG dynamics, linking its function to stress responses and potential disease mechanisms.

The same abstract notes: "Impaired SG disassembly is closely implicated in neurodegenerative diseases and aging." Since VCP itself is a Mendelian neurodegeneration gene (MSP1/IBMPFD, ALS/FTD), an OTUD6B–VCP condensate axis is a plausible neural mechanism. Caveat: this work is in non‑neuronal cell lines and makes no claim about IDDFSDA. Curate as EMERGING hypothesis + IN_VITRO evidence source.

6.5 Enzyme‑independent scaffolding: the pVHL/HIF‑1α axis

PMID:32328410 (Adv Sci 2020) and PMID:32323143 (Protein Cell 2020) independently show OTUD6B stabilizes pVHL without using its catalytic activity, verbatim from PMID:32328410:

OTUD6B directly interacts with pVHL, decreases its ubiquitylation and proteasomal degradation to reduce HIF-1α accumulation in HCC cells under hypoxia. Surprisingly, OTUD6B limits the ubiquitylation of pVHL independent of its deubiquitylase activity. OTUD6B couples pVHL and elongin B/C to form more CBCVHL ligase complex, which protects pVHL from proteasomal degradation. […] Furthermore, OTUD6B gene is a direct transcriptional target of HIF-1α and upregulated upon hypoxia.

Curation implication: this is why catalytically‑dead missense variants may not fully phenocopy null alleles — OTUD6B has at least one non‑catalytic scaffolding function. This directly bears on interpreting the mild p.Tyr216Cys phenotype. It also predicts that OTUD6B loss should raise HIF‑1α — a testable but untested hypothesis in patient tissue.

6.6 Additional characterized functions (not established in the NDD)

⚠️ The human vs. zebrafish IRF3 direction is explicitly contradictory — PMID:37650650 says so directly: "unlike the previous report that zebrafish OTUD6B negatively regulates the antiviral response by suppressing K63-linked ubiquitination of IRF3 and IRF7, we demonstrate that human OTUD6B actually enhances type I IFN response." This is a textbook HUMAN_MODEL_MISMATCH discussion candidate.

6.7 Suggested ontology terms for the pathograph

GO biological process / molecular function — all verified against OLS:

⚠️ Verify with OAK before use (uv run runoak -i sqlite:obo:go info <ID> -O obo): GO:0031929 TOR signaling; GO:0007420 brain development; GO:0021987 cerebral cortex development; GO:0006915 apoptotic process.

Cell types (CL) — ⚠️ all require OAK verification: CL:2000001 peripheral blood mononuclear cell (the only cell type with direct patient‑derived experimental data) · CL:0000540 neuron · CL:0000127 astrocyte (HPA: "Subsets of astrocytes show general, distinct and intense staining throughout the brain") · CL:0000121 Purkinje cell (HPA: somato‑dendritic staining) · CL:0000746 cardiac muscle cell · CL:0000542 lymphocyte (cytoplasmic inclusions).

7. Anatomical Structures Affected

7.1 Organ level

Primary (directly and consistently affected): - Central nervous system — the dominant organ system. Cortex (ID, seizures, autistic behavior), corpus callosum (hypoplasia 3/12), ventricular system (ventriculomegaly), white matter, with reported cortical atrophy. UBERON:0000955 brain; UBERON:0002336 corpus callosum (verified); UBERON:0000956 cerebral cortex (⚠️ verify); lateral ventricle (⚠️ verify ID). - Musculoskeletal system — hands and feet (broad distal phalanges, tapered fingers, clubfoot, overlapping toes, polydactyly), vertebral column (scoliosis, vertebral anomaly), joints (flexion contractures). - Craniofacial complex — the recognizable gestalt; brachycephaly, flat occiput, retrognathia, high palate, ears (macrotia, low‑set, protruding). - Heart — septal defects (ASD 3/6, VSD 2/6) and conotruncal malformation (Tetralogy of Fallot). Interventricular/interatrial septum are the specific sites; the mouse model independently confirms septation as the vulnerable structure.

Secondary / less consistent: - Gastrointestinal tract (feeding difficulties, chronic constipation) - Genitourinary (cryptorchidism; renal cortical cysts in one blended‑phenotype case) - Thyroid gland (hypothyroidism, ≥3 patients) - Immune system (hypogammaglobulinemia, ≥3 patients) - Eye — optic disc, retina (single case, 2025) - Ear/auditory (hearing impairment) - Teeth/oral (macrodontia, dental crowding, delayed eruption, thick alveolar ridges) - Skin/adnexa (soft doughy skin, hypohidrosis; long eyelashes)

Body systems involved: nervous, cardiovascular, musculoskeletal, digestive, endocrine, immune, genitourinary, integumentary, special senses. This breadth is expected for a defect in a ubiquitously expressed proteostasis enzyme and is why the disorder was framed from the outset as "multisystemic."

7.2 Tissue and cell level

Human Protein Atlas (ENSG00000155100): OTUD6B has low tissue specificity — "Detected in all," tau specificity score 0.24, clustered as "Non-specific — Basic cellular processes." Protein‑level tissue enhancement is noted in cerebral cortex and lymphoid tissue. Within brain, HPA reports immunoreactivity in astrocytes ("Subsets of astrocytes show general, distinct and intense staining throughout the brain"), cerebellar Purkinje cells (somato‑dendritic staining), and choroid plexus cells, across hippocampal formation, cerebral cortex, and cerebellum.

The mouse Otud6b^tm1b^ lacZ reporter independently confirmed near‑ubiquitous expression: per PMC5384096 full text (⚠️ verify), lacZ expression was "nearly ubiquitous" across cardiovascular, nervous, digestive, and musculoskeletal systems.

Implication for curation: there is no evidence for a tissue‑restricted or cell‑type‑restricted primary lesion. The tissue distribution of disease reflects differential vulnerability to proteostasis failure (post‑mitotic neurons, rapidly proliferating embryonic cardiac/limb mesenchyme) rather than restricted gene expression. Model this explicitly rather than implying neural‑specific expression.

7.3 Subcellular level

• Cytosol (GO:0005829, ⚠️ verify) — HPA reports cytoplasmic localization; primary site of proteasome assembly and translation initiation.
• Proteasome complex (GO:0000502, ⚠️ verify) / proteasome regulatory particle — the site of the demonstrated 19S assembly defect.
• Cytoplasmic stress granule (GO:0010494, ⚠️ verify) — demonstrated OTUD6B localization (PMID:41651815).
• Centrosome and mitotic spindle (⚠️ verify IDs) — "OTUD6B can localise to centrosomes and the mitotic spindle" (PMID:39789388).
• Cytoplasmic inclusions in patient lymphocytes — a pathological subcellular finding, not a normal compartment.

7.4 Localization and lateralization

Findings are bilateral and symmetric throughout: microcephaly, corpus callosum hypoplasia (a midline structure), bilateral ventriculomegaly ("mild irregular enlargement of the bilateral lateral ventricles," PMID:41188742), symmetric distal limb anomalies of both hands and feet, and midline septal cardiac defects. No lateralized or asymmetric presentation is reported. Note: the bilateral hand+foot involvement pattern makes this a candidate — though not a demonstrated one — for comparison against the limb_digit_patterning_serial_homology module; but OTUD6B is a proteostasis gene, not a limb‑patterning morphogen, so conformance would be phenotypic rather than mechanistic and is not recommended without evidence.

8. Temporal Development

8.1 Onset

• Antenatal: IUGR (7/12, HPO onset HP:0030674); congenital heart defects detectable prenatally (one family terminated a pregnancy for antenatally diagnosed ToF, PMID:35707595); congenital brain malformations.
• Neonatal/infantile: hypotonia, feeding difficulties, microcephaly (HPO onset HP:0003593 Infantile onset), nystagmus (detected at 6 months in the Chinese case).
• Infancy (1–23 months, per GARD): seizures, developmental delay becomes apparent.
• Onset pattern: congenital / insidious, not acute. There is no asymptomatic interval and no acute presenting crisis.
• Orphanet records age of onset as infancy.

8.2 Progression

No formal staging system, no natural‑history study, no longitudinal cohort exists. What can be stated:

• Course: chronic, lifelong. The encephalopathy is best characterized as static/developmental rather than neurodegenerative — imaging findings are malformative (corpus callosum hypoplasia, ventriculomegaly) rather than showing documented progressive loss. (Orphanet's mention of "cortical atrophy" is the one datum pointing the other way; whether it represents progressive atrophy or congenital hypoplasia is unresolved.)
• Seizures: recurrent/episodic on a chronic background. Refractoriness is implied by PMID:32924626's framing of seizure control as "the current challenge" but has not been systematically reported.
• Secondary progression: scoliosis, joint contractures, and spastic tetraplegia are expected to progress with growth in the severe group — this is an inference from the phenotype set, not a cited longitudinal finding.
• Duration: lifelong; no self‑limited component.
• Remission: none. No spontaneous or treatment‑induced remission of the core phenotype has been reported or would be expected.

8.3 Critical periods

• Embryonic organogenesis (weeks 4–8): the window during which cardiac septation and limb patterning are established. Both the human cardiac phenotype and the mouse VSD phenotype localize the vulnerability here. No intervention is possible in this window.
• Fetal/perinatal: the mouse model narrows lethality precisely — homozygotes "survived to E18.5 at expected frequencies," with death occurring between E18.5 and shortly after birth (PMC5384096, ⚠️ verify). This identifies the perinatal transition as the critical survival bottleneck in mice, though human patients survive it.
• Infancy–early childhood: the only actionable window — for seizure control, feeding support, early intervention/therapy, and detection of the treatable comorbidities (hypothyroidism, hypogammaglobulinemia).

⚠️ Flag: everything in §8.2–8.3 beyond the mouse data is inference. This section is the weakest‑evidenced part of the entity and should carry an explicit KNOWLEDGE_GAP discussion for natural history.

9. Inheritance and Population

9.1 Epidemiology

An alternative dismech Prevalence record with measure_type: CASES_IN_LITERATURE and rate_per_100000 omitted would faithfully capture the ~28‑case count; use the Orphanet band for the population rate.

9.2 Genetic epidemiology

• Inheritance pattern: Autosomal recessive (HP:0000007). Confirmed by ClinGen Definitive curation (AR), OMIM, Orphanet, and segregation in every reported family (both parents heterozygous carriers). GARD states the standard recurrence figures: "there is a 25% chance their child will have the disease and a 50% chance the child will be a carrier."
• Penetrance: appears complete for biallelic pathogenic genotypes. No unaffected biallelic individual has been reported. However, with n≈30 and complete ascertainment bias toward affected probands, non‑penetrance for hypomorphic genotypes cannot be excluded — a mildly affected biallelic adult would very likely never be sequenced.
• Expressivity: highly variable, both between and within families (PMID:34354232: "our patients showed inter- and intrafamilial differences with regard to the clinical and brain imaging findings"). Genotype accounts for much but not all of the variance (§3.3).
• Genetic anticipation: not applicable — no repeat expansion mechanism.
• Germline mosaicism: not reported; recurrence risk counselling should follow standard AR (25%) figures.
• Founder effects: none formally established. c.433C>T (p.Arg145*) recurs in three of the six original families and in the Mexican proband — worth a haplotype study, but published as independent occurrences (a CpG→TpG transition at an arginine codon is a recurrent‑mutation hotspot signature, which is at least as parsimonious as a founder haplotype). Do not assert a founder effect.
• Consanguinity: the dominant epidemiological driver. Homozygous genotypes predominate; families are reported from Turkey, Egypt (two unrelated consanguineous families), the Gulf/Saudi region, Mexico, Spain, Italy, and China. PMID:34354232 draws the methodological conclusion directly: "demonstrating the need for in-depth analysis of WES data in consanguineous families to uncover simultaneous autosomal recessive disorders."
• Carrier frequency: not established. gnomAD LOEUF 1.48 / pLI 0 indicates pLoF alleles are present in the population at low frequency, but no carrier‑frequency estimate has been published. Reported disease alleles are absent or <10⁻⁵ in gnomAD.

9.3 Population demographics

• Affected populations: no ethnic group has a demonstrated elevated prevalence. The apparent concentration in Middle Eastern, North African, Mediterranean, and Latin American reports reflects consanguinity rates and access to exome sequencing, not a population‑specific allele.
• Geographic distribution: worldwide; reported from Europe (Italy, Spain), Middle East/North Africa (Turkey, Egypt, Saudi Arabia), the Americas (Mexico, USA), and East Asia (China — first case only in 2025).
• Variant geography: no variant is geographically restricted in a way that establishes a founder allele.
• Sex ratio: expected 1:1 (autosomal). Reported cases include both sexes with no documented skew; n is too small for a meaningful ratio.
• Age distribution: the reported population is overwhelmingly pediatric (infants through school age). There are essentially no published adult patients, which is itself an information gap — it is unknown whether this reflects reduced survival, diagnostic ascertainment bias toward children in the exome era, or both.

10. Diagnostics

10.1 Clinical tests

There is no biochemical screening test, no biomarker, and no functional assay in clinical use for this disorder. Diagnosis is molecular. Supporting/complication‑detection investigations:

Research‑only cellular assays (not clinically available, but of high mechanistic value — and the basis of any future functional‑evidence framework for VUS interpretation): - Native PAGE of PBMC lysates for 19S/26S proteasome assembly (Rpn5, Rpt6 incorporation) - 26S chymotrypsin‑like peptidase activity assay - Anti‑ubiquitin immunoblot for ubiquitin‑protein conjugate accumulation - Light microscopy for cytoplasmic lymphocyte inclusions

Biopsy/histopathology: no diagnostic biopsy indicated; no characteristic histopathology described beyond the lymphocyte inclusions.

No LOINC‑coded disease‑specific test exists.

10.2 Genetic testing — the diagnostic route

Recommended approach: trio exome or genome sequencing, with parallel or reflex chromosomal microarray.

Critical WES‑interpretation caveat, twice demonstrated: in consanguineous families, a second homozygous recessive disorder may coexist and confound phenotyping. PMID:34354232 found homozygous RP1L1 nonsense variants explaining retinal degeneration that had initially been attributed to OTUD6B; PMID:35707595 found a heterozygous PKD1 variant explaining renal cysts. Do not attribute every feature in a proband to OTUD6B without checking the rest of the exome.

10.3 Omics‑based diagnostics

• RNA‑seq / transcriptomics: not in clinical use for this disorder; targeted RT‑PCR for splice variants is the practical alternative (§10.2).
• Proteomics: research only. Note that proximity proteomics (BioID‑style) was the discovery method for the OTUD6B–VCP interaction (PMID:41651815).
• Metabolomics / lipidomics: no signature described. No data available.
• Epigenomics: no episignature published. Given demonstrated Kabuki‑syndrome mimicry, an OTUD6B episignature would be a high‑value diagnostic development — currently a gap, not a resource.
• Liquid biopsy: not applicable.

10.4 Clinical criteria and differential diagnosis

No formal consensus diagnostic criteria exist (no society guideline, no DSM/ICD operational criteria, no GeneReviews chapter as of this review). Diagnosis = compatible phenotype + biallelic pathogenic OTUD6B variants.

A clinically recognizable gestalt is claimed but contested. PMID:38389298 puts it precisely: "Physical differences described for affected individuals suggest that the disorder may be clinically recognizable, but previous publications have reported an initial clinical suspicion for Kabuki syndrome (KS) in some affected individuals." The most specific reported sign is from PMID:34354232 — broad distal phalanges of thumbs and halluces with prominent interphalangeal joints and persistent fetal pads, described as "pathognomonic." (⚠️ "Pathognomonic" is the authors' assertion from a 5‑patient, 2‑family series; treat as a strong clinical pearl, not an established specificity claim.)

Differential diagnosis — each entry below is grounded in an actual published misdiagnosis or clinical suspicion, which makes this an unusually well‑evidenced DDx:

10.5 Screening

• Newborn screening: not included in any NBS panel; no biochemical marker exists to enable it. Notably, the Chinese proband's hypothyroidism was detected on routine newborn metabolic screening — an incidental route to earlier attention, not a screen for the disorder itself.
• Carrier screening: OTUD6B is included in some expanded carrier‑screening panels (⚠️ panel‑dependent; verify with GTR before asserting). Justified in consanguineous couples and in families with an affected relative.
• Cascade screening: standard AR cascade — test at‑risk siblings and offer carrier testing to relatives once the familial variants are known.
• Prenatal / preimplantation: available once both familial variants are characterized (see §13).

11. Outcome / Prognosis

⚠️ This section is the most evidence‑poor in the report. There is no survival study, no mortality figure, no life‑expectancy estimate, no disability‑outcome measure, and no validated prognostic model for OTUD6B‑related disorder. What follows distinguishes the few citable facts from clinical inference.

11.1 Survival and mortality

• Human survival data: none published. No 5‑year or 10‑year survival figure, no mortality rate, no disease‑specific mortality estimate exists. The published cohort is pediatric and cross‑sectional.
• The published population contains essentially no adults, which is itself the only survival‑adjacent signal — and it is confounded by the recency of the gene discovery (2017) and by exome‑era ascertainment favoring children.
• Mouse mortality is severe and well‑characterized, but does not transfer to humans: homozygous Otud6b knockouts are subviable with near‑complete perinatal lethality (MGI: "complete perinatal lethality"; PMC5384096: only 2 of 97 births, p<1×10⁻⁵, both died at birth). Human patients with predicted‑null biallelic genotypes survive infancy, so the mouse null overstates human lethality. This is a genuine HUMAN_MODEL_MISMATCH — model it as such, not as a survival prediction.
• Expected principal mortality contributors, by analogy with comparable severe syndromic encephalopathies (inference, uncited): aspiration/respiratory infection in feeding‑tube‑dependent non‑ambulatory patients; complications of congenital heart disease; status epilepticus.

11.2 Morbidity and function

• Severe group: profound functional impairment — non‑verbal, non‑ambulatory ("inability to walk"), spastic tetraplegia, total care dependence, gastrostomy feeding. ICF‑level disability is severe across mobility, communication, and self‑care domains.
• Mild group: mild‑to‑moderate ID with preserved speech and ambulation; substantially better functional prognosis.
• No QoL instrument has been applied (no EQ‑5D, SF‑36, PROMIS, or disease‑specific PROM). See §3.3.

11.3 Complications

Documented: recurrent seizures; feeding failure and aspiration risk; failure to thrive/short stature; congenital heart disease and its sequelae; progressive scoliosis and contractures; hypothyroidism; hypogammaglobulinemia (with attendant infection risk); hearing impairment; visual impairment (single case); constipation.

Recovery potential: none for the core neurodevelopmental phenotype. Developmental gains occur but the underlying encephalopathy is not reversible with any current intervention. Treatable comorbidities (hypothyroidism, seizures, CHD, nutrition) are the domains where intervention changes outcome.

11.4 Prognostic factors

The only supported prognostic factor is genotype severity class: - Biallelic predicted‑null (nonsense/frameshift/canonical splice, both alleles) → severe phenotype - Hypomorphic missense or leaky splice on ≥1 allele → milder phenotype

PMID:35430327 formalized this with molecular‑dynamics modelling: p.Tyr216Cys (mild) → "localized destabilization"; p.Ile274Arg (severe) → "significant distortion in the overall fold of OTUD6B." Its own conclusion is appropriately hedged: "However, additional functional studies are required."

Additional plausible but unvalidated prognostic markers: presence/severity of microcephaly; age at seizure onset and seizure control; presence of CHD; degree of structural brain malformation on MRI. None is validated.

Prognostic biomarkers: none. The proteasome‑assembly assay is a candidate quantitative severity readout (given the observed WT < het < hom gradient) but has never been correlated with clinical outcome. This is a concrete, tractable research proposal worth recording as a proposed_experiments item.

12. Treatment

There is no disease‑modifying, targeted, or curative therapy for OTUD6B‑related neurodevelopmental disorder. Management is entirely symptomatic, supportive, and anticipatory. No clinical trial has ever been registered for this disorder (ClinicalTrials.gov search: no OTUD6B‑specific trials). No FDA/EMA‑approved therapy exists. No pharmacogenomic guidance (CPIC/PharmGKB: zero high‑level records for OTUD6B, per ClinGen).

The literature contains no treatment protocol; the closest statement of intent is PMID:32924626: "The current challenge with this patient is to ensure medical management of his seizures and provide him with a better quality of life. The possibilities of additional therapeutic approaches may increase by understanding the physiopathology of the involved pathways."

12.1 Management components with suggested NCIT terms

⚠️ All NCIT IDs below require verification (uv run runoak -i sqlite:obo:ncit info <ID> and just validate-terms). They are supplied as curation candidates, not verified bindings. Treatments in this section are standard‑of‑care inferences for syndromic ID with epilepsy, not OTUD6B‑specific published recommendations — this must be stated explicitly in any KB entry.

12.2 Advanced therapeutics — status

12.3 Treatment outcomes, adverse events, algorithms

• Response rates: no data. No treatment has been formally evaluated in this disorder.
• Adverse events: no disorder‑specific safety signal reported. No published contraindication or pharmacogenomic interaction.
• Treatment algorithms / clinical pathways: none published; no NCCN/society guideline. Care should follow generic multidisciplinary syndromic‑ID pathways.
• Combination therapy / personalized medicine: not applicable at present. The only genotype‑informed element of care is prognostic counselling based on the null‑vs‑hypomorph severity split (§11.4).

12.4 Actionable, evidence‑based surveillance recommendation

The single most useful management statement in the literature is the screening recommendation from PMID:32924626, which should be carried into the KB entry:

In addition to seizures and other more frequently reported manifestations of this condition, this is the third patient with associated hypothyroidism and hypogammaglobulinemia, underscoring the value of screening for these conditions in other patients.

To which PMID:41188742 adds ophthalmological evaluation. Baseline workup at diagnosis should therefore include: echocardiogram, brain MRI, EEG, thyroid function tests, serum immunoglobulins, ophthalmological examination with fundoscopy, audiology, and spine imaging.

13. Prevention

Because this is a fully penetrant monogenic recessive disorder with no environmental component, prevention means reproductive genetics — not risk‑factor modification.

13.1 Primary prevention

• Not achievable by any behavioral, dietary, environmental, or public‑health intervention. There is no modifiable risk factor.
• Genetic counseling is the primary preventive intervention. NCIT:C15240 (⚠️ verify). For carrier couples: 25% recurrence per pregnancy, 50% carrier, 25% unaffected non‑carrier (GARD).
• Preconception carrier screening, particularly in consanguineous couples and in communities with high consanguinity rates, is the highest‑yield population‑level measure.
• Preimplantation genetic testing for monogenic disease (PGT‑M) and prenatal diagnosis (CVS/amniocentesis) are available once both familial variants are molecularly characterized. These are the only interventions that prevent occurrence.

13.2 Secondary prevention (early detection)

• Cascade testing of siblings and at‑risk relatives after a proband diagnosis.
• Early molecular diagnosis of a symptomatic infant — the practical benefit is not disease modification but (a) ending the diagnostic odyssey, (b) triggering the surveillance protocol in §12.4, and (c) enabling accurate recurrence counselling before the next pregnancy.
• Note the incidental‑detection route: the Chinese proband's hypothyroidism was picked up on routine newborn metabolic screening, which brought her to medical attention at 6 months.
• No population screening program exists or is proposed, and none is justified at a prevalence of <1/1,000,000 with no presymptomatic treatment.

13.3 Tertiary prevention (preventing complications in diagnosed patients)

This is where prevention is genuinely actionable: - Systematic screening for hypothyroidism and hypogammaglobulinemia (explicitly recommended, PMID:32924626) — both are treatable and both, if missed, add avoidable morbidity. - Echocardiography at diagnosis to detect surgically correctable CHD. - Ophthalmological and audiological assessment to prevent avoidable sensory‑deprivation contributions to developmental delay. - Aspiration prevention via feeding assessment and, where indicated, gastrostomy. - Scoliosis and contracture surveillance with early orthopedic and physiotherapy intervention. - Seizure control optimization.

13.4 Not applicable

• Immunization: no disease‑specific vaccine strategy. (Standard childhood immunization applies; if hypogammaglobulinemia is present, live‑vaccine caution and immunological input follow standard immunodeficiency practice — ⚠️ inference, not published for this disorder.)
• Public‑health / environmental interventions: not applicable.
• Chemoprophylaxis: none, unless antimicrobial prophylaxis is indicated for a documented antibody deficiency (⚠️ inference).

14. Other Species / Natural Disease

14.1 Taxonomy and orthologs

⚠️ Caution: MGI:1922805 is not Otud6b (it is Nsmce3l). Use MGI:1919451.

14.2 Natural disease in other species

None reported. There is no naturally occurring OTUD6B‑related disease in any companion animal, livestock species, or wildlife population. A search of the veterinary literature and OMIA yields no OTUD6B entry (⚠️ OMIA was not directly queried in this review — verify at omia.org before asserting absence definitively).

Veterinary relevance: none. All animal OTUD6B disease models are experimentally induced, not natural.

14.3 Comparative biology

• Evolutionary conservation: OTUD6B is conserved across vertebrates, with functional orthologs demonstrated in mouse, rat, and zebrafish. The OTU catalytic domain and its cysteine‑protease triad are the deeply conserved elements.
• Comparative pathology — a key mismatch. The mouse null is substantially more severe than the human null: homozygous Otud6b^tm1b/tm1b^ mice are subviable with essentially complete perinatal lethality, whereas human patients with biallelic predicted‑null alleles survive into childhood. Conversely, the cardiac phenotype is strikingly concordant — mouse VSD at high penetrance vs. human ASD/VSD/ToF — making the heart the best cross‑species‑validated organ.
• Direction‑of‑effect divergence in innate immunity: the human vs. zebrafish IRF3 results are explicitly opposite (§6.6). This is a documented species divergence, not merely an unreplicated result, and should be curated as HUMAN_MODEL_MISMATCH rather than as conflicting evidence for a single claim.
• Transmission / zoonosis / cross‑species susceptibility: not applicable — this is a germline monogenic disorder.

15. Model Organisms

15.1 Mouse — the principal disease model

Allele: Otud6b^tm1b(EUCOMM)Wtsi (MGI:5637064) — a knockout‑first tm1a converted to tm1b by Cre‑mediated excision of the promoter‑driven neo cassette and critical exon(s), leaving a lacZ reporter in place. This design is what enabled the expression mapping.

Repositories: MGI records 10 mutations/alleles for Otud6b (2 endonuclease‑mediated, 4 gene‑trapped, 4 targeted) and 29 strains/lines available through IMSR. A line is archived at MRC Harwell (B6Dnk;B6N-Otud6b^tm1b(EUCOMM)Wtsi/WtsiCnbc, stock 7042). IMPC phenotyping data at mousephenotype.org/data/genes/MGI:1919451.

Phenotype (MGI summary): "complete perinatal lethality, decreased fetal size, and ventricular septal defects," with annotations spanning cardiovascular, growth/size, hematopoietic, immune, and mortality/aging systems, from 13 phenotype references.

Detailed findings (PMC5384096 full text — ⚠️ paraphrase‑risk, verify before use as snippets): - Subviability: only 2 homozygotes identified from 97 births (p<1×10⁻⁵ deviation from Mendelian expectation); both died at birth. - Timing of lethality: homozygotes survived to E18.5 at expected frequencies → death occurs between E18.5 and shortly after birth. This is a precise and useful window. - Growth: E18.5 knockout embryos showed 34% reduced total volume vs. wild‑type littermates — a direct correlate of the human IUGR/growth restriction phenotype. - Cardiac: ventricular septal defects in 80% of hearts (3/3 at E14.5; 1/2 at E18.5) vs. a 0.67% background rate in C57BL/6N controls. - Expression: lacZ reporter expression "nearly ubiquitous," across cardiovascular, nervous, digestive, and musculoskeletal systems.

IMPC phenotyping (mousephenotype.org, MGI:1919451): 2 significant phenotypes; 3 of 21 tested physiological systems significantly impacted — mortality/aging, immune system, hematopoietic system (18 systems no significant impact, 3 not tested). Note that the immune and hematopoietic hits are independently interesting given the human hypogammaglobulinemia reports and the B‑lymphocyte cell‑cycle work (PMID:21267069).

15.2 Phenotype recapitulation and limitations

Limitations — this is the crux of the model problem and should be curated as an explicit HUMAN_MODEL_MISMATCH discussion:

The constitutive mouse null is too severe to model the defining features of the human disease. Because homozygotes die at birth, the model cannot address intellectual disability, seizures, speech, ambulation, microcephaly, or any postnatal neurodevelopmental outcome — i.e., the entire clinical core of IDDFSDA. What the mouse does establish is the embryonic arm: cardiac septation and fetal growth. The human null phenotype is milder than the mouse null, meaning there is either species‑specific redundancy (possibly OTUD6A or other OTU‑family paralogs) or a difference in developmental dependence on the enzyme.

Proposed experiments to resolve the mismatch (proposed_experiments candidates): 1. Conditional/neural‑specific Otud6b knockout (e.g., Nestin‑Cre, Emx1‑Cre) to bypass perinatal lethality and interrogate cortical development, seizure susceptibility, and behavior. 2. Hypomorphic knock‑in of the human missense alleles (p.Tyr216Cys as the "mild" allele; p.Ile272Arg/p.Ile274Arg as the "severe" allele) to test the genotype–severity model computationally proposed by PMID:35430327 in an in‑vivo system. 3. Patient iPSC‑derived cortical neurons and cerebral organoids — currently the most important missing model. No iPSC or organoid model of OTUD6B deficiency has been published. This would permit direct testing of the proteasome‑assembly defect in human neurons and of the mTORC1‑translation and stress‑granule hypotheses in the disease‑relevant cell type. 4. Correlate the PBMC proteasome‑assembly assay with clinical severity across a genotype‑stratified patient cohort, to test whether it functions as a quantitative severity biomarker.

15.3 Other model systems

Model databases: MGI (informatics.jax.org/marker/MGI:1919451), IMPC (mousephenotype.org/data/genes/MGI:1919451), IMSR (29 strains), EUCOMM/EMMA, MRC Harwell (stock 7042), ZFIN, RGD, Alliance of Genome Resources.

Consolidated Evidence Register

References with verbatim abstracts captured in this report (suitable for snippet: after just fetch-reference + just validate-references):

Structured‑database citations available: ORPHA:505237 (Orphanet — definition, prevalence <1/1,000,000, ICD‑10 Q87.8, AR inheritance, infancy onset) and a CGGV: ClinGen gene‑disease validity record (OTUD6B / syndromic intellectual disability / AR / Definitive / ID and Autism GCEP / 2024‑08‑22). Both should be pulled through the repo's structured‑source pipeline (just structured-rebuild-orphanet --id 505237, just clingen-refresh + just clingen-list) rather than hand‑transcribed.

Prioritized Knowledge Gaps

1. No natural history study. Survival, life expectancy, adult outcomes, and progression rate are entirely unknown. There are effectively no published adult patients.
2. No iPSC / cortical organoid model. The mouse null's perinatal lethality means the human disease's defining features (ID, seizures, microcephaly) have never been modelled in any system. This is the single largest mechanistic gap. → HUMAN_MODEL_MISMATCH.
3. The link from proteasome dysfunction to the neural phenotype is unestablished. The 19S assembly defect is demonstrated in PBMCs; nothing connects it to cortical development, neuronal excitability, or seizure generation. The mTORC1‑translation and stress‑granule/VCP routes are plausible bridges but are EMERGING hypotheses from non‑neuronal cells.
4. Direction of effect on neural progenitor proliferation is unknown — OTUD6B is anti‑proliferative in one system and pro‑proliferative in another. Is microcephaly proliferative or apoptotic in origin?
5. No episignature, despite documented Kabuki‑syndrome mimicry — a tractable diagnostic development.
6. HPOA frequencies derive from a single, severity‑biased 12‑person cohort and conflict with later mild cases (e.g., "Severe intellectual disability 12/12").
7. The proteasome‑assembly assay has never been correlated with clinical severity despite showing a clean WT<het<hom gradient — an obvious candidate quantitative biomarker.
8. Genotype–severity model is computational only (PMID:35430327's own caveat: "additional functional studies are required"), and intrafamilial variability argues that genotype is not the whole story.

Sources

Literature (PubMed): PMID:28343629 · PMID:30364145 · PMID:31147255 · PMID:32181568 · PMID:32924626 · PMID:34354232 · PMID:34680978 · PMID:35430327 · PMID:35707595 · PMID:38389298 · PMID:41188742 · PMID:27864334 · PMID:21267069 · PMID:36059274 · PMID:39789388 · PMID:41651815 · PMID:32328410 · PMID:33421002 · PMID:34183367 · PMID:37650650 · PMID:35662507 · PMID:40527635 · PMC5384096 (AJHG full text) · PMC12584513 (BMC Pediatr full text)

Databases and aggregators: OMIM #617452 · OMIM *612021 · Orphanet ORPHA:505237 · MedGen C4479520 · GARD 17942 · HPO annotations (ontology.jax.org) · ClinGen OTUD6B (HGNC:24281) · HGNC REST (OTUD6B) · UniProt Q8N6M0 · Human Protein Atlas ENSG00000155100 · MGI:1919451 (mouse Otud6b) · MGI:5637064 (Otud6b tm1b allele) · IMPC MGI:1919451 · MRC Harwell stock 7042 · ClinVar and PubMed queried via NCBI E‑utilities · OLS4 (EBI) for GO/UBERON/MONDO verification